Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus PRED G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus PRED G.
DUREZOL vs PRED-G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Prednisolone acetate is a glucocorticoid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; gentamicin sulfate is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to 30S ribosomal subunit.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
1 drop of the ophthalmic suspension (containing prednisolone acetate 1% and gentamicin sulfate 0.3%) into the affected eye(s) every 2-4 hours during the day, then taper as clinical signs improve. For severe disease, 1 drop every hour initially.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
The terminal elimination half-life of gentamicin (the active component) is approximately 2–3 hours in adults with normal renal function. In neonates, half-life is prolonged to 5–11 hours. The immunosuppressive component (prednisolone) has a half-life of 2–4 hours.
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
Renal excretion accounts for approximately 70% of elimination, with the remainder as unchanged drug in feces (20%) and biliary excretion (10%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination